Search results

535 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]

In development [GID-TA10651] Expected publication date: 02 February 2022

Type

Technology appraisal guidance

Status

In development
Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

In development [GID-TA10451] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]

In development [GID-TA10710] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

In development [GID-TA10560] Expected publication date: 03 February 2021

Type

Technology appraisal guidance

Status

In development
Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: 03 February 2021

Type

Technology appraisal guidance

Status

In development
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID1313]

In development [GID-TA10312] Expected publication date: 24 February 2021

Type

Technology appraisal guidance

Status

In development
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]

In development [GID-TA10734] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mental health community settings

In development [GID-SGWAVE0702] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Inpatient mental health settings

In development [GID-SGWAVE0701] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Community nursing care settings

In development [GID-SGWAVE0700] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Management and organisational approaches to safe staffing

In development [GID-SGWAVE0761] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Accident and emergency departments

In development [GID-SGWAVE0762] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

In development [GID-MT163] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

In development [GID-MT536] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Obesity - phentermine (with topiramate) [ID543]

In development [GID-TAG439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]

In development [GID-TAG372] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

In development [GID-TAG423] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer - intensity modulated radiotherapy [ID17]

In development [GID-TAG396] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Colon cancer (adjuvant) - irinotecan [ID379]

In development [GID-TAG380] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

In development [GID-TAG330] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer (hormone refractory) - atrasentan [ID390]

In development [GID-TAG379] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

In development [GID-TAG300] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

In development [GID-TAG440] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Clostridium difficile associated diarrhoea - tolevamer [ID378]

In development [GID-TAG389] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]

In development [GID-TAG405] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

In development [GID-TAG384] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

In development [GID-TAG388] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development